Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma
10.1007/s13139-019-00602-0
- Author:
Sun Ha BOO
1
;
Joo Hyun O
;
Soo Jin KWON
;
Ie Ryung YOO
;
Sung Hoon KIM
;
Gyeong Sin PARK
;
Byung Ock CHOI
;
Seung Eun JUNG
;
Seok Goo CHO
Author Information
1. Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea. ojoohyun@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Follicular lymphoma;
¹⁸F-fluorodeoxyglucose;
Positron emission tomography;
Lugano classification;
Progression-free survival
- MeSH:
Disease-Free Survival;
Drug Therapy;
Electrons;
Fluorodeoxyglucose F18;
Humans;
Kaplan-Meier Estimate;
Lymphoma;
Lymphoma, Follicular;
Multivariate Analysis;
Positron-Emission Tomography;
Positron-Emission Tomography and Computed Tomography;
Retrospective Studies
- From:Korean Journal of Nuclear Medicine
2019;53(4):263-269
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PET(Interim)) and end-of-induction therapy PET/CT (PET(EOI)) in patients with FL.METHODS: FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PET(Interim) was performed 3 or 4 cycles after chemotherapy and PET(EOI) after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (−), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan-Meier survival analysis, and the log-rank test.RESULTS: Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CTstudies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5–72.7 months). On PET(Interim), 23 patients were negative and 10 were positive. On PET(EOI) scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PET(EOI)(−) was associated with longer PFS. PET(Interim)(+) and PET(EOI)(+) patients had a significantly shorter PFS than PET(Interim)(−) patients (39.9 months, 95%confidence interval [CI] 23.0–56.9, versus 55.5months, 95%CI 49.7–61.2, p=0.005) and PET(EOI)(−) patients (14.2 months, 95% CI 8.5–19.8, versus 60.5 months, 95% CI 52.1–69.0, p<0.001).CONCLUSION: For patients with FL, PET(Interim) and PET(EOI) response is predictive of PFS, and PET(EOI)(+) is an independent prognostic factor for progression of FL.
